Platelet protection in coronary artery surgery: Benefits of heparin- coated circuits and high-dose aprotinin therapy

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 4, 1999, Pages 388-392

  Wendel, Hans Peter ^a   Schulze, Hans Joachim ^b   Heller, Wolfgang ^b   Hoffmeister, Hans Martin ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

Aprotinin; Biocompatibility; Cardiopulmonary bypass surgery; Extracorporeal circulation; Heparin coating; Platelet membrane receptors; Platelets

Indexed keywords

APROTININ; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; KALLIKREIN; THROMBOCYTE FACTOR 4;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD OXYGENATION; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY SURGERY; EXTRACORPOREAL CIRCULATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

EID: 0032817725     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(99)90208-2     Document Type: Article

References (41)

1. Gibbon JR: Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37:171-180, 1954
2. Woodman RC, Harker LA: Bleeding complications associated with cardiopulmonary bypass. Blood 76:1680-1697, 1991
3. Didisheim D, Watson J: Thromboembolic complications of cardiovascular devices and artificial surfaces, in Kwaan H, Samama MY (eds): Clinical Thrombosis. Boca Raton, FL, CRC, 1989, pp 275-296
4. Anderson AB, Tran TH, Hamilton MJ, et al: Platelet deposition and fibrinogen binding on surfaces coated with heparin or friction-reducing polymers. AJNR Am J Neuroradiol 17:859-863, 1996
5. Gravlee GP: Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesth 8:213-222, 1994
6. Bidstrup BP, Harrison J, Royston D, et al: Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 55:971-976, 1993
7. Dietrich W, Barankay A, Hähnel C, Richter JA: High-dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 6:324-327, 1992
8. Royston D, Bidstrup BP, van Oeveren W, et al: Reduction in blood loss following open heart surgery: Beneficial effect of high-dose aprotinin. Anaesth Intensive Care 17:20-25, 1986
9. Davis R, Whittington R: Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 49:954-983, 1995
10. Wildevuur CRH, Eijsman L, Roozendaal KJ, et al: Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 3:533-538, 1989
11. van Oeveren W, Harder MP, Roozendaal KJ, et al: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788-796, 1990
12. Lavee J, Savion N, Smolinsky A, et al: Platelet protection by aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 53:477-481, 1992
13. Wahba A, Philip A, Bauer MF, et al: The blood saving potential of vortex versus roller pump with and without aprotinin. Perfusion 10:333-341, 1995
14. Heller W, Wendel HP: Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation. Blood Coagul Fibrinolysis 4:45-54, 1993
15. Pelzer H, Fuhge P, Heimburger N: Enzyme immunoassay for the determination of human platelet factor 4: Blut 49:123-124, 1984
16. Carvalho AC, DeMarinis S, Scott CF, et al: Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 112:270-277, 1988
17. Müller E: Adult respiratory distress syndrome (ARDS): Activation of complement, coagulation and fibrinolytic systems. Biomed Prog 4:3-6, 1991
18. Colman RW: Hemostatic complications of cardiopulmonary bypass. Am J Hematol 48:267-272, 1995
19. Andrade JD, Hlady V, Wei AP, et al: Proteins at interfaces: Principles, multivariate aspects, protein resistant surfaces, and direct imaging and manipulation of adsorbed proteins. Clin Mater 11:67-84, 1992
20. Mulzer SR, Brash JL: Analysis of proteins adsorbed to glass from human plasma using immunoblotting methods. J Biomater Sci Polym Ed 1:173-182, 1990
21. Vroman L: The life of an artificial device in contact with blood: Initial events and their effect on its final state. Bull NY Acad Med 64:352-357, 1988
22. Stanford MF, Munoz PC, Vroman L: Platelets adhere where flow has left fibrinogen on glass. Ann NY Acad Sci 416:504-512, 1983
23. Gluszko P, Rucinski B, Musial J, et al: Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 252:H615-H621, 1987
24. Boldt J, Zickmann B, Czeke A, et al: Blood conservation techniques and platelet function in cardiac surgery. Anaesthesiology 75:426-432, 1991
25. Rinder CS, Bohnert J, Rinder HM, et al: Platelet activation and aggregation during cardiopulmonary bypass. Anaesthesiology 75:388-393, 1991
26. Harker LA: Bleeding after cardiopulmonary bypass. N Engl J Med 314:1446-1447, 1986
27. Wenger RK, Lukasiewicz H, Mikuta BS, et al: Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 97:235-239, 1989
28. Palatianos GM, Dewanjee MK, Smith NO, et al: Platelet preservation during cardiopulmonary bypass with Iloprost and Duraflo-II heparin-coated surfaces. Trans Am Soc Artif Int Organs 37:620-622, 1991
29. Borowiec JW, Thelin S, Bagge L, et al: Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 26:177-185, 1992
30. Thelin S, Bagge L, Hultman J, et al: Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Eur J Cardiothorac Surg 5:486-491, 1991
31. Wachtfogel YT, Kucich U, Hack CE, et al: Aprotinin inhibits the contact; Neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-10, 1993
32. Mohr R, Goor DA, Lusky A, Lavee J: Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation 86:405-409, 1992
33. Cramer EM, Lu H, Caen JP, et al: Different redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 77:694-699, 1991
34. Lu H, Soria C, Cramer EM, et al: Temperature dependence of plasmin-induced platelet activation or inhibition of human platelets. Blood 77:996-1105, 1991
35. Tabuchi N, De Haan J, Boonstra PW, et al: Aprotinin effect on platelet function and clotting during cardiopulmonary bypass. Eur J Cardiothorac Surg 8:87-90, 1994
36. Orchard MA, Goodchild CS, Prentice CRM, et al: Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 85:533-541, 1993
37. Blauhut B, Gross C, Necek S, et al: Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 101:958-967, 1991
38. Wendel HP, Heller W, Gallimore MJ: Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model. Immunopharmacology 32:128-131, 1996
39. Gallagher JM, Brown ME, Gasior TA: Combined use of aprotinin and a heparin-bonded cardiopulmonary bypass system for aortic aneurysm repair. J Cardiothorac Vasc Anesth 9:728-730, 1995
40. Baufreton C, Jansen PG, Le Besnerais P, et al: Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg 63:50-56, 1997
41. Jansen PG, Baufreton C, Le Besnerais P, et al: Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann Thorac Surg 61:1363-1366, 1996